BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20(43): 16029-16036 [PMID: 25473155 DOI: 10.3748/wjg.v20.i43.16029]
URL: https://www.wjgnet.com/1007-9327/full/v20/i43/16029.htm
Number Citing Articles
1
Lara Aguilera Castro, Carlos Martín de Argila de Prados, Agustín Albillos Martínez. Practical considerations in the management of proton-pump inhibitorsRevista Española de Enfermedades Digestivas 2015;  doi: 10.17235/reed.2015.3812/2015
2
Shan Jing, Yue Zhu, Wenfang Liu, Kexu Yang, Lili Hu, Dan Deng, Chunyan Lu, Yang Lin. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled TrialAdvances in Therapy 2021; 38(3): 1660 doi: 10.1007/s12325-021-01644-7
3
Jun Zhang, Jing Zhong, Jian Ding, Jiemin Shi, Tao Tang, Qiqi Liu, Huilian Huang, Licheng Dai, Ningmin Yang. Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kitJournal of Global Antimicrobial Resistance 2018; 13: 174 doi: 10.1016/j.jgar.2017.12.018
4
Pedro Cortés, Alfred D. Nelson, Yan Bi, Fernando F. Stancampiano, Loren P. Murray, George G.A. Pujalte, Victoria Gomez, Dana M. Harris. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive ReviewJournal of Primary Care & Community Health 2021; 12: 215013272110140 doi: 10.1177/21501327211014087
5
He-Jian Zhang, Xue-Hui Zhang, Jie Liu, Lu-Ning Sun, Yi-Wen Shen, Chen Zhou, Hong-Wen Zhang, Li-Jun Xie, Juan Chen, Yun Liu, Yong-Qing Wang. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitorsPharmacological Research 2020; 152: 104606 doi: 10.1016/j.phrs.2019.104606
6
Muhamad A. K. Shakhatreh, Omar F. Khabour, Karem H. Alzoubi, Mohammed N. BaniHani, Ahmed Abu-Siniyeh, Nabil A. Bashir, Salsabeel H. Sabi, Mahmoud Mahafdah. <p>The Influence of <em>IL-1B</em> Gene Polymorphisms on <em>H. pylori</em> Infection and Triple Treatment Response Among Jordanian Population</p>The Application of Clinical Genetics 2020; : 139 doi: 10.2147/TACG.S253778
7
Wen Zhong Liu, Yong Xie, Hong Lu, Hong Cheng, Zhi Rong Zeng, Li Ya Zhou, Ye Chen, Jiang Bin Wang, Yi Qi Du, Nong Hua Lu. Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfectionHelicobacter 2018; 23(2): e12475 doi: 10.1111/hel.12475
8
Shailja Shah, Elizabeth Hubscher, Corey Pelletier, Rinu Jacob, Lydia Vinals, Rena Yadlapati. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failureExpert Review of Gastroenterology & Hepatology 2022; 16(4): 341 doi: 10.1080/17474124.2022.2056015
9
Xiaoye Shi, Chunmei Wang, Fanjun Meng, Shaoze Ma, Guangqin Xu, Tingwei Liu, Xiaozhong Guo, Hongyu Li, Xingshun Qi. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational studyPostgraduate Medicine 2022; : 1 doi: 10.1080/00325481.2022.2105094
10
Chao-Hung Kuo, Chung-Jung Liu, Ching-Chia Yang, Fu-Chen Kuo, Huang-Ming Hu, Hsiang-Yao Shih, Meng-Chieh Wu, Yen-Hsu Chen, Hui-Min David Wang, Jian-Lin Ren, Deng-Chyang Wu, Lin-Li Chang. A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric JuiceMedicine 2016; 95(21): e3458 doi: 10.1097/MD.0000000000003458
11
Malek Zihlif, Banan Bashaireh, Mohammed Rashid, Zaid Almadani, Yazun Jarrar. Effect of major CYP2C19 genetic polymorphisms on Helicobacter pylori eradication based on different treatment regimensBiomedical Reports 2021; 16(1) doi: 10.3892/br.2021.1485
12
Lili Yang, Ao Zou, Huihua Wu, Hai Guo, Fangting Zhang, Bing Zou, Junping Wang, Emily Chia-Yu Su. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pyloriBioMed Research International 2021; 2021: 1 doi: 10.1155/2021/6150628
13
Jihee Sung, Nayoung Kim, Yo Han Park, Young Jae Hwang, Soohoon Kwon, Gyeongjae Na, Joon Young Choi, Jae Bin Kang, Hye Rang Kim, Jin-Wook Kim, Dong Ho Lee. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with forHelicobacter pyloriEradication FailureThe Korean Journal of Gastroenterology 2017; 69(2): 109 doi: 10.4166/kjg.2017.69.2.109
14
Martin Klieber, Herbert Oberacher, Silvia Hofstaetter, Beate Beer, Martin Neururer, Anton Amann, Hannes Alber, Anil Modak. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized MedicineJournal of Pharmacology and Experimental Therapeutics 2015; 354(3): 426 doi: 10.1124/jpet.115.225680
15
I V Maev, D N Andreev. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapyTerapevticheskii arkhiv 2017; 89(8): 5 doi: 10.17116/terarkh20178985-12
16
Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin, In Sung Song. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for <italic>Helicobacter pylori</italic> infectionWorld Journal of Gastroenterology 2015; 21(46): 13124-13131 doi: 10.3748/wjg.v21.i46.13124
17
Álvaro Vela, Carmen Guerrero. Análisis del polimorfismo CYP2C19*2 en la población castellanoleonesaFarmaJournal 2020; 5(1): 95 doi: 10.14201/fj20205195104
18
Hideki Mori, Hidekazu Suzuki. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid BlockerJournal of Neurogastroenterology and Motility 2019; 25(1): 6 doi: 10.5056/jnm18139
19
Siya Kong, Keting Huang, Jun Wang, Xiaoyong Wang, Ningmin Yang, Yu Dong, Ya Zhuang, Yini Dang, Guoxin Zhang, Feng Ye. Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective studyGut Pathogens 2020; 12(1) doi: 10.1186/s13099-020-00378-1
20
Yi Hu, Yin Zhu, Nong-Hua Lu. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic ResistanceFrontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00168
21
Jeffrey Fong. PharmacotherapyFirst: A Multimedia Learning Resource2017;  doi: 10.21019/pharmacotherapyfirst.pud_overview
22
Yi Song, Fengna Dou, Zhe Zhou, Ningmin Yang, Jing Zhong, Jie Pan, Qiqi Liu, Jianzhong Zhang, Shengqi Wang. Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 PatientsBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/2684836
23
Jaeyoung Kim, Yeon-Ji Kim, Woo Chul Chung. Proton Pump Inhibitor Switching Strategy after Failure of Standard Triple Therapy for Helicobacter pylori InfectionThe Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020; 20(2): 146 doi: 10.7704/kjhugr.2019.0036
24
Pratsanee Hiengrach, Wimonrat Panpetch, Ariya Chindamporn, Asada Leelahavanichkul. Helicobacter pylori, Protected from Antibiotics and Stresses Inside Candida albicans Vacuoles, Cause Gastritis in MiceInternational Journal of Molecular Sciences 2022; 23(15): 8568 doi: 10.3390/ijms23158568
25
Sotirios D Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Treatment ofHelicobacter Pyloriinfection: optimization strategies in a high resistance eraExpert Opinion on Pharmacotherapy 2015; 16(15): 2307 doi: 10.1517/14656566.2015.1084503
26
Maliheh Safavi, Reyhaneh Sabourian, Alireza Foroumadi. Treatment of <i>Helicobacter pylori</i> infection: Current and future insightsWorld Journal of Clinical Cases 2016; 4(1): 5-19 doi: 10.12998/wjcc.v4.i1.5
27
Enzo Ierardi, Giuseppe Losurdo, Rosa Federica La Fortezza, Mariabeatrice Principi, Michele Barone, Alfredo Di Leo. Optimizing proton pump inhibitors in <i>Helicobacter pylori</i> treatment: Old and new tricks to improve effectivenessWorld Journal of Gastroenterology 2019; 25(34): 5097-5104 doi: 10.3748/wjg.v25.i34.5097
28
Xue‐Feng Zhong, Gan Zhou, Su‐Mei Xu, Xiao‐Min Li, Ying Xu, Wan‐Li Liu, Yan‐Xin Zhang, Lin‐Cong He, Qiu‐Ying Shen, Ping‐Sheng Xu. Pharmacokinetics of Esomeprazole Magnesium After Single Oral Doses in Healthy Subjects: Bioequivalence Study and Food EffectsClinical Pharmacology in Drug Development 2022;  doi: 10.1002/cpdd.1139
29
You-hua Wang, Zhi-fa Lv, Yao Zhong, Dong-sheng Liu, Shu-ping Chen, Yong Xie. The internalization ofHelicobacter pyloriplays a role in the failure ofH. pylorieradicationHelicobacter 2017; 22(1): e12324 doi: 10.1111/hel.12324
30
Anil S Modak. Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical needJournal of Breath Research 2017; 12(1): 017101 doi: 10.1088/1752-7163/aa8d2e
31
Cailing Li, Yanyan Shi, Baojun Suo, Xueli Tian, Liya Zhou, Zhiqiang Song. PPI‐amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta‐analysis Helicobacter 2021; 26(4) doi: 10.1111/hel.12816
32
James P. Franciosi, Edward B. Mougey, Andre Williams, Roberto A. Gomez-Suarez, Cameron Thomas, Christa L. Creech, Katherine George, Diana Corao, John J. Lima. Association BetweenCYP2C19*17Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal RefluxThe Journal of Clinical Pharmacology 2018; 58(1): 89 doi: 10.1002/jcph.977
33
Hiroyuki Eto, Sho Suzuki, Chika Kusano, Hisatomo Ikehara, Ryoji Ichijima, Hirotaka Ito, Koichi Kawabe, Masashi Kawamura, Yoshioki Yoda, Moriyasu Nakahara, Takuji Gotoda. Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy Helicobacter 2021; 26(2) doi: 10.1111/hel.12788
34
Juan Fu, Chang-Feng Sun, Hong-Yan He, Suvash Chandra Ojha, Han Shi, Cun-Liang Deng, Yun-Jian Sheng. The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysisPharmacogenomics 2021; 22(13): 859 doi: 10.2217/pgs-2020-0127
35
Hyasinta Jaka, Andreas Mueller, Christa Kasang, Stephen E. Mshana. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective studyBMC Infectious Diseases 2019; 19(1) doi: 10.1186/s12879-019-4085-1
36
Daphne Ang, Seok Hwee Koo, Yiong Huak Chan, Thean Yen Tan, Gaik Hong Soon, Chin Kimg Tan, Kenneth Weicong Lin, Jaydeesh‐Khanna Krishnasamy‐Balasubramanian, Yu Jun Wong, Rahul Kumar, Rajesh R, Yiyuan Tan, Peng‐Lan Jeannie Ong, Yi‐Lyn Jessica Tan, James Weiquan Li, Andrew Boon‐Eu Kwek, Tiing Leong Ang. Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication Alimentary Pharmacology & Therapeutics 2022; 56(3): 436 doi: 10.1111/apt.17070
37
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysisGene Reports 2021; 25: 101340 doi: 10.1016/j.genrep.2021.101340
38
Lian-Di Kan, Jie Chen, Yue-Ting Huang, Yang Qiu, Xin-Lu Yu, Hong-Mei Fang, Qin Chen, Liu-Cheng Li. Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradicationClinical and Experimental Medicine 2020; 20(4): 609 doi: 10.1007/s10238-020-00643-2
39
Azucena Arévalo Galvis, Alba Alicia Trespalacios Rangel, William Otero Regino. Personalized therapy for Helicobacter pylori : CYP2C19 genotype effect on first‐line triple therapy Helicobacter 2019; 24(3): e12574 doi: 10.1111/hel.12574
40
Regis R Vieira, Luís Eduardo S Fontes, Rafael L Pacheco, Marcos AP Fernandes, Paloma P Malta, Rachel Riera. Proton pump inhibitor- and clarithromycin-based triple therapies for Helicobacter pylori eradicationCochrane Database of Systematic Reviews 2020; 2021(8) doi: 10.1002/14651858.CD013734
41
Chao Ran Ji, Jing Liu, Yue Yue Li, Chen Qiao, Jun Yan Qu, Jun Nan Hu, Min Juan Lin, Rui Ji, Li Xiang Li, Xiu Li Zuo, Yan Qing Li. Susceptibility‐guided quadruple therapy is not superior to medication history‐guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial Journal of Digestive Diseases 2020; 21(10): 549 doi: 10.1111/1751-2980.12934
42
Azza Abbas, Sawazen Malik, Bushra Sulieman, Khalid Enan. Detection of CYP2C19*2_ allele among Helicobacter pylori -infected patients in two tertiary hospitals of Khartoum, Sudan, 2019F1000Research 2021; 10: 1063 doi: 10.12688/f1000research.73724.1
43
Mohammed N. BaniHani, Omar F. Khabour, Karem H. Alzoubi, Nabil A. Bashir, Muhamad Ali K. Shakhatreh, Salsabeel H. Sabi, Nasr Alrabadi. The Association between ABCB1 C1236T/C3435T SNPs and H. pylori Infection among JordaniansGenes 2020; 11(1): 63 doi: 10.3390/genes11010063
44
Su Young Kim, Duck Joo Choi, Jun-Won Chung. Antibiotic treatment for <italic>Helicobacter pylori</italic>: Is the end coming?World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 183-198 doi: 10.4292/wjgpt.v6.i4.183
45
D N Andreev, D T Dicheva, I V Maev. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practiceTerapevticheskii arkhiv 2017; 89(2): 84 doi: 10.17116/terarkh201789284-90
46
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseasesPharmacology & Therapeutics 2016; 168: 12 doi: 10.1016/j.pharmthera.2016.08.001
47
Muhammad Miftahussurur, Dalla Doohan, Ari Fahrial Syam, Iswan Abbas Nusi, Phawinee Subsomwong, Langgeng Agung Waskito, Hasan Maulahela, Fardah Akil, Willy Brodus Uwan, Gontar Siregar, Kartika Afrida Fauzia, Yudith Annisa Ayu Rezkitha, Abdul Rahman, I Dewa Nyoman Wibawa, Alexander Michael Joseph Saudale, Marselino Richardo, Titong Sugihartono, Alvi Chomariyati, Taufan Bramantoro, Tomohisa Uchida, Yoshio Yamaoka. CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical OutcomesBiology 2021; 10(4): 300 doi: 10.3390/biology10040300
48
Shailja C. Shah, Prasad G. Iyer, Steven F. Moss. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert ReviewGastroenterology 2021; 160(5): 1831 doi: 10.1053/j.gastro.2020.11.059
49
Ying Zhou, Ziqing Ye, Yuhuan Wang, Ye Zhang, Zifei Tang, Weili Yan, Yuan Jiang, Ying Huang. Comparison of four different regimens against Helicobacter pylori as a first‐line treatment: A prospective, cross‐sectional, comparative, open trial in Chinese children Helicobacter 2020; 25(2) doi: 10.1111/hel.12679
50
Yi-Chung Lee, Yi-Chu Liao, Feng-Chi Chang, Hui-Chi Huang, Jui-Yao Tsai, Chih-Ping Chung. Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese populationJournal of the Chinese Medical Association 2019; 82(6): 469 doi: 10.1097/JCMA.0000000000000101
51
Denis S. Fedorinov, Karin B. Mirzaev, Dmitriy V. Ivashchenko, Ilyas I. Temirbulatov, Dmitriy A. Sychev, Nadezda R. Maksimova, Jana V. Chertovskih, Nyurguiana V. Popova, Ksenia S. Tayurskaya, Zoya A. Rudykh. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)Drug Metabolism and Personalized Therapy 2018; 33(2): 91 doi: 10.1515/dmpt-2018-0004
52
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapyJournal of Antimicrobial Chemotherapy 2019; 74(1): 11 doi: 10.1093/jac/dky401
53
Irina Yurievna Kolesnikova, Irina Vyacheslavovna Ivakhnenko, Anzhelika Viktorovna Ponomareva, Sergey Ivanovich Krayushkin. Modern aspects of eradication therapySpravočnik vrača obŝej praktiki (Journal of Family Medicine) 2020; (12): 36 doi: 10.33920/med-10-2012-05
54
Keliang Wang, Dandi Lou, Wei Dai, Rongrong Fu, Zhenhua Ma. Comparison of sequential therapy with concomitant therapy in first-line treatment of Helicobacter pylori: an updated meta-analysis Journal of Medical Microbiology 2022; 71(1) doi: 10.1099/jmm.0.001490
55
Luyi Chen, Jiamin He, Lan Wang, Qiwei Ge, Hua Chu, Yujia Chen, Xiaoli Chen, Yanqin Long, Yanyong Deng, Huiqin He, Aiqing Li, Shujie Chen. Efficacies of different proton pump inhibitor-based 14-day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trialClinical and Experimental Medicine 2018; 18(4): 569 doi: 10.1007/s10238-018-0510-9